Gamma Biosciences’ bioseparation business Astrea will use the Affimer technology to expand its range of ligand discovery and development capabilities. Avacta Group’s Affimer reagents are small proteins that have a binding surface that can be tailored to capture a target molecule of interest out of complex mixtures encountered in biomanufacturing. “The Affimer reagent technology was originally developed at the MRC Cancer Unit in Cambridge UK for proteomics applications and was acquired by Avacta in 2012,” Alastair Smith, CEO of Avacta…